1![UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor](https://www.pdfsearch.io/img/23a419056168e2ff76b0399a0f4bea51.jpg) | Add to Reading ListSource URL: www.neuro.uni-luebeck.deLanguage: German - Date: 2014-03-27 09:47:19
|
---|
2![Guideline on CT in Small Populations - Adopted Guideline on CT in Small Populations - Adopted](https://www.pdfsearch.io/img/fdf1dd98dfe454bca7889083588bd048.jpg) | Add to Reading ListSource URL: www.ema.europa.euLanguage: English - Date: 2013-07-21 04:57:34
|
---|
3![MayImproving Trial Success by Improving Tumor Assessment Jamal Gasmi, MD, PhD l Vice President & Global Leader Oncology & Hematology Drug Development, ICON Clinical Research James Conklin, MD, MS l Senior Vice Pre MayImproving Trial Success by Improving Tumor Assessment Jamal Gasmi, MD, PhD l Vice President & Global Leader Oncology & Hematology Drug Development, ICON Clinical Research James Conklin, MD, MS l Senior Vice Pre](https://www.pdfsearch.io/img/bd35262845b37b6a3bfa9f2dd6322402.jpg) | Add to Reading ListSource URL: www.aptivsolutions.comLanguage: English - Date: 2013-08-16 10:39:06
|
---|
4![Updated Results of Phase 1b of Tarextumab (TRXT, OMP-59R5, anti-Notch 2/3) in Combination with Etoposide and Platinum Therapy (EP) in Patients (pts) with Untreated Extensive-Stage Small Cell Lung Cancer (ED-SCLC) Copies Updated Results of Phase 1b of Tarextumab (TRXT, OMP-59R5, anti-Notch 2/3) in Combination with Etoposide and Platinum Therapy (EP) in Patients (pts) with Untreated Extensive-Stage Small Cell Lung Cancer (ED-SCLC) Copies](https://www.pdfsearch.io/img/437e4f10d26faf37363f2f4dd9de3204.jpg) | Add to Reading ListSource URL: s3.amazonaws.comLanguage: English - Date: 2016-06-04 05:53:42
|
---|
5![Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunot Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunot](https://www.pdfsearch.io/img/83701ac0b08eebad4b7da14fa90d89c7.jpg) | Add to Reading ListSource URL: www.argostherapeutics.comLanguage: English - Date: 2013-12-05 12:55:41
|
---|
6![April 23, 2015 POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it ha April 23, 2015 POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced it ha](https://www.pdfsearch.io/img/ca6287145002cc0a06c691b81ffb55af.jpg) | Add to Reading ListSource URL: www.pomalyst.comLanguage: English - Date: 2015-12-12 00:14:44
|
---|
7![Retraction Pfizer, Inc., has recently learned that the overall response rate and progression-free survival data published in “Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 Retraction Pfizer, Inc., has recently learned that the overall response rate and progression-free survival data published in “Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871](https://www.pdfsearch.io/img/7caf38f0d8fe773e8aeb6008acbf39d2.jpg) | Add to Reading ListSource URL: jco.ascopubs.orgLanguage: English - Date: 2012-10-24 19:18:58
|
---|
8![Crizotinib / Macular edema / Anaplastic lymphoma kinase / Macula of retina / Non-small-cell lung carcinoma / Progression-free survival / Central retinal vein occlusion / Medicine / Ranibizumab / Bevacizumab Crizotinib / Macular edema / Anaplastic lymphoma kinase / Macula of retina / Non-small-cell lung carcinoma / Progression-free survival / Central retinal vein occlusion / Medicine / Ranibizumab / Bevacizumab](/pdf-icon.png) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2015-01-19 17:21:09
|
---|
9![Microsoft PowerPoint - lokhorst Kos.ppt [Read-Only] [Compatibility Mode] Microsoft PowerPoint - lokhorst Kos.ppt [Read-Only] [Compatibility Mode]](https://www.pdfsearch.io/img/65774e85230be504634faaf7b2e20a20.jpg) | Add to Reading ListSource URL: myeloma.orgLanguage: English - Date: 2012-04-18 11:55:00
|
---|
10![NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication REGORAFENIB NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication REGORAFENIB](https://www.pdfsearch.io/img/a3ba79c17d570a99dc32d6bb2c43eaed.jpg) | Add to Reading ListSource URL: www.england.nhs.ukLanguage: English - Date: 2013-10-02 06:24:46
|
---|